parsaclisib
Selected indexed studies
- Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. (Am J Hematol, 2024) [PMID:39435908]
- Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. (Transfus Med Hemother, 2024) [PMID:39371250]
- Management of autoimmune hemolytic anemia. (Hematology Am Soc Hematol Educ Program, 2025) [PMID:41347987]
_Worker-drafted node — pending editorial review._
Connections
parsaclisib is a side effect of
Sources
- Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. (2024) pubmed
- Autoimmune Hemolytic Anemias: Challenges in Diagnosis and Therapy. (2024) pubmed
- Management of autoimmune hemolytic anemia. (2025) pubmed
- Parsaclisib in Japanese patients with relapsed or refractory B-cell lymphoma (CITADEL-111): A phase Ib study. (2022) pubmed
- Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study. (2023) pubmed
- Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study. (2023) pubmed
- PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma. (2025) pubmed
- Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study. (2023) pubmed
- Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. (2020) pubmed
- Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study. (2023) pubmed